MEETING REPORT
Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR)

https://doi.org/10.1111/ajt.14990Get rights and content
Under a Creative Commons license
open archive

The Lung session of the 2017 14th Banff Foundation for Allograft Pathology Conference, Barcelona focused on the multiple aspects of antibody-mediated rejection (AMR) in lung transplantation. Multidimensional approaches for AMR diagnosis, including classification, histological and immunohistochemical analysis, and donor- specific antibody (DSA) characterization with their current strengths and limitations were reviewed in view of recent research. The group also discussed the role of tissue gene expression analysis in the context of unmet needs in lung transplantation. The current best practice for monitoring of AMR and the therapeutic approach are summarized and highlighted in this report. The working group reached consensus of the major gaps in current knowledge and focused on the unanswered questions regarding pulmonary AMR. An important outcome of the meeting was agreement on the need for future collaborative research projects to address these gaps in the field of lung transplantation.

Keywords

alloantibody
classification systems: Banff classification
clinical research/practice
histocompatibility
lung (allograft) function/dysfunction
lung transplantation/pulmonology
microarray/gene array
pathology/histopathology
rejection: antibody-mediated (ABMR)

Abbreviations

Ab
antibody
ACR
acute cellular rejection
AMR
antibody-mediated rejection
anti-AT1R
angiotensin type 1 receptor
ATG
anti-thymocyte globulin
CLAD
chronic lung allograft dysfunction
DSA
donor-specific antibody
ISHLT
International Society for Heart and Lung Transplantation
PFT
pulmonary function test
RAT
rejection-associated transcript
SAB
single-antigen bead array
TCMR
T cell–mediated rejection

Cited by (0)